A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple- Dose Ranging, Adaptive Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B Virus Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2015

At a glance

  • Drugs Vesatolimod (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top